Frank Torti’s Next 100 Days: Active, Not Just Acting, FDA Commissioner
This article was originally published in The Rose Sheet
Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count
You may also be interested in...
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle